RxDoctor Payments Data

Meghan Blay, DO

Family Medicine · Lees Summit, MONPI 1205241973

Payments from drug & device makers

$1,747in general payments, 2019–2025

Across 74 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$392
  • AbbVie$313
  • Amgen$313
  • Vanda Pharmaceuticals Inc.$160
  • Novo Nordisk$150
  • AstraZeneca$93
  • plus $326 from 11 others

What the payments were for

  • Food & beverage$1,747100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,747 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$84,998
Medicare patients
278
Services billed
2,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$56,279
RybelsusSemaglutide29$30,008
JardianceEmpagliflozin24$29,977
EliquisApixaban11$15,459
FarxigaDapagliflozin Propanediol13$10,351
GemtesaVibegron11$10,129
SynthroidLevothyroxine Sodium35$2,256
Albuterol Sulfate HfaAlbuterol Sulfate70$2,235
Atorvastatin Calcium243$2,074
Gabapentin164$1,981
Omeprazole158$1,797
Celecoxib36$1,730
Potassium Chloride43$1,514
Levothyroxine Sodium204$1,355
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$150$86,28785 claims
PfizerEliquis$34$15,45911 claims
AstraZenecaFarxiga$93$10,35113 claims
Sumitomo Pharma America, Inc.Gemtesa$24$10,12911 claims
AbbVieSynthroid$313$2,25635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →